WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that company management will present at two upcoming investor conferences: Lori Freedman , vice president

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that on November 27, 2013 , the United Kingdom's National Institute for Health and Care Excellence (NICE)

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended September 30, 2013 .

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the first quarter of fiscal year 2014 will be released after the

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc.

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at the 4 th Annual Biosimilars & Biobetters Conference being held October 1 and 2 in

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2013 .

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2013 will be released after the

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at two upcoming investor conferences in September.

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, has announced that pSivida President and Chief Executive Officer, Paul Ashton , Ph.D., will speak

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the Transparency Commission (Commission de la Transparence or CT) of the French

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (Nasdaq: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced that it has priced an underwritten public offering of 3,494,550 shares of its

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (Nasdaq: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced that it intends to offer and sell shares of its common stock in a proposed

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced interim data from an investigator-sponsored Phase I/II study of pSivida's

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that it has initiated the first of two planned pivotal Phase III trials of its

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV - News ), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Excellence (NICE) issued draft

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that it has signed a funded technology evaluation agreement with a leading global

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its third quarter ended March 31, 2013 .

WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV - News ), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that ILUVIEN ® , the first sustained release pharmaceutical product for the treatment of chronic